Want to see BDRX full AI Analyst Report?
Biodexa Pharmaceuticals (BDRX) AI Stock Analysis
Biodexa Pharmaceuticals
(NASDAQ:BDRX)
BDRX scores near the bottom of the range. The dominant driver is weak financial performance: zero revenue, recurring losses, and negative operating and free cash flow leave the company entirely reliant on dilutive equity financing, despite a debt-free balance sheet and a welcome halving of cash burn in 2025. Compounding this, the technical trend is deeply negative, with the share price far below all major moving averages and negative MACD momentum. Valuation offers no offset, as earnings are negative and no dividend is paid. This profile fits a high-risk, speculative biotech whose outcome hinges on clinical milestones and continued access to capital rather than current fundamentals.
Biodexa Pharmaceuticals (BDRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $319.90K
- Dividend Yield
- ―
- Average Volume (3M)
- 621.20K
- Price to Earnings (P/E)
- -52.2
- Beta (1Y)
- 0.93
- Revenue Growth
- ―
- EPS Growth
- 97.97%
- Country
- US
- Employees
- 11
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Biodexa Pharmaceuticals Business Overview & Revenue Model
Company Description
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Mid...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Biodexa’s primary way of generating cash is typically not from recurring product sales but from financing and, when applicable, deal-based revenue tied to its drug development programs. Key potential rev...
Biodexa Pharmaceuticals Financial Statement Overview
Summary
Biodexa is a pre-revenue clinical-stage biotech with zero revenue in 2024 and 2025, negative gross profit, and persistent net losses (~$6.2M in 2025) alongside deeply negative EBIT/EBITDA (~-$8.3M/-$8.1M). Cash flow remains fully negative (operating and free cash flow of -$5.4M in 2025), with no internally generated cash. The only relative strength is the balance sheet: stockholders' equity rose to ~$11.4M and total assets to ~$18.1M on the back of equity raises, with virtually no debt (D/E of 0.005). Cash burn was cut by more than half versus 2024 and ROE improved to -54.8%, but equity growth is driven by dilutive financing rather than operations, leaving a limited runway and complete dependence on capital markets.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 381.00K | 699.00K | 578.00K |
| Gross Profit | -129.28K | -184.86K | -5.44M | -3.69M | -4.41M | -4.08M |
| EBITDA | -4.68M | -8.08M | -8.95M | -7.16M | -8.09M | -5.66M |
| Net Income | -4.44M | -6.24M | -5.73M | -7.08M | -7.66M | -5.46M |
Balance Sheet | ||||||
| Total Assets | 12.64M | 18.15M | 14.78M | 10.54M | 5.53M | 12.91M |
| Cash, Cash Equivalents and Short-Term Investments | 3.21M | 8.52M | 1.67M | 5.97M | 2.84M | 10.06M |
| Total Debt | 0 | 60.89K | 727.00K | 464.00K | 624.00K | 766.00K |
| Total Liabilities | 3.09M | 6.76M | 6.46M | 5.86M | 2.36M | 2.46M |
| Stockholders Equity | 9.55M | 11.38M | 8.32M | 4.68M | 3.16M | 10.45M |
Cash Flow | ||||||
| Free Cash Flow | -6.95M | -5.40M | -13.04M | -7.09M | -7.11M | -6.33M |
| Operating Cash Flow | -6.94M | -5.39M | -12.26M | -6.83M | -7.05M | -6.01M |
| Investing Cash Flow | -1.04M | -658.25K | -598.00K | -265.00K | -220.00K | -278.00K |
| Financing Cash Flow | 7.12M | 12.77M | 8.56M | 10.23M | 47.00K | 8.80M |
Biodexa Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 3.18 is below the 20-day moving average (MA) of 3.61, below the 50-day MA of 5.43, and below the 200-day MA of 24.94, indicating a bearish trend. The MACD of -0.65 indicates Negative momentum. The RSI at 34.95 is Neutral, neither overbought nor oversold. The STOCH value of 37.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.
Biodexa Pharmaceuticals Risk Analysis
Biodexa Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Biodexa Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBiodexa Pharmaceuticals Peers Comparison
Overall Rating
INDP51Neutral
INM48Neutral
CNSP42Neutral- BDRX38Underperform
ENVB26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| INDP | 51Neutral | $474.57M | -0.50 | -302.75% | ― | ― | 81.43% |
| INM | 48Neutral | $8.79M | -0.47 | -134.73% | ― | -60.74% | 66.05% |
| CNSP | 42Neutral | $7.31M | -0.19 | -204.25% | ― | ― | 88.43% |
| BDRX | 38Underperform | $1.80M | -52.22 | -42.42% | ― | ― | 97.97% |
| ENVB | 26Underperform | $6.40M | -0.09 | -168.05% | ― | ― | 87.05% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals Plc | 2.80 | -213.20 | -98.70% | |
| INDP | Indaptus Therapeutics, Inc. | 3.50 | 0.66 | 23.24% | |
| INM | Inmed Pharmaceuticals Inc. | 1.63 | -0.10 | -5.78% | |
| ENVB | Enveric Biosciences, Inc. | 1.45 | -4.25 | -74.56% | |
| CNSP | Cns Pharmaceuticals, Inc. | 4.39 | -2.21 | -33.48% |
Biodexa Pharmaceuticals Corporate Events
Biodexa Reaches 100-Patient Milestone in Phase 3 Serenta Trial for FAP
Biodexa Pharmaceuticals reported on October 13, 2026 that it has enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis, a hereditary condition that can lead to colorectal cancer and currently lac...
Biodexa Pharmaceuticals Announces Reverse ADS Ratio Change Effective Late October 2026
On October 8, 2026, Biodexa Pharmaceuticals announced it will change the ratio of its American Depositary Shares, moving from one ADS representing 50 ordinary shares to one ADS representing 400 ordinary shares, effective on or about October 26, 2026....
Biodexa Pharmaceuticals Secures $2.3 Million Via Warrant Exercise Deal
On September 14–15, 2026, Biodexa Pharmaceuticals PLC entered into a warrant inducement agreement with an accredited investor to trigger the full exercise of outstanding Series M, N and O warrants. The investor agreed to exercise warrants for 2...
Biodexa Pharmaceuticals Posts Interim 1H26 Results and Expands GI Cancer Pipeline
On September 11, 2026, Biodexa Pharmaceuticals reported unaudited interim results for the six months ended June 30, 2026, highlighting progress across its gastrointestinal cancer pipeline. During the period, the company in-licensed MTX240 for GIST fr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026